Learn more about Trulieve: Website | IR Website | Investor Deck | TRUL Chart, Follow TCI on Social Media: Facebook | Instagram | Twitter | LinkedIn | Investor Group, Follow Psychedelic Profits on Social Media: Facebook | Twitter | LinkedIn | Investor Group. Bottomley states, “Given Trulieve’s healthy financial position, access to capital, and best-in-class profitability metrics, we believe the stock is attractive for investors looking for cannabis exposure to a high-quality operator with a proven ability to generate strong EBITDA and profitability.”. Featured ArticlesCannabis Stock NewsCannabis Industry ArticlesTechnical Analysis ArticlesWatch Cannabis Stock Videos, This U.S. Cannabis Stock Appears to Be Way Undervalued and May Actually Benefit From a Second Wave of the Pandemic. “Green Thumb remains our top pick among U.S. cannabis stocks, together with Trulieve,” added Zuanic.
Shoot us an email & let’s chat! In contrast, the lowest price target comes from Andrew Semple of Echelon Wealth Partners with a C$33 price target and a buy rating. Start Your Risk-Free Trial Subscription Here, Pfizer (NYSE:PFE) Stock: A Strong Option for Dividend Investors.
Tesla (NASDAQ: TSLA) is off -10% on a day that the broader markets continue an extended slump, following a very, Our first recurring guest on our Spotlight Series is that of Chris Naprawa, whom is now the Chairman of Khiron, Mind Cure Health (CSE: MCUR) has received the required authorizations from Health Canada for its functional mushroom products to begin. Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Not a recommendation to buy or sell. Benzinga’s Take: Given all the uncertainty that remains in the cannabis space in the near-term, it may be wise for cannabis bulls to take a diversified approach to investing.
Last week, Trulieve Cannabis (CSE: TRUL) announced that they are acquiring two Pennsylvania companies, PurePen LLC and Solevo Wellness, which will make them a fully integrated Pennsylvania cannabis company while also expanding their footprint to five states. The current 12-month mean price target is C$40.11 or a 34.15% upside, Pablo Zuanic from Cantor Fitzgerald has a C$70 price target and a buy rating on the stock. Even with that, Andrew says, “we believe Q2/20’s outperformance matched with historical conservatism on the part of management could offset future headwinds.” They raised their full-year 2020 and 2021 revenue estimates to U$489.6 million and U$660.2 million, respectively. Learn about financial terms, types of investments, trading strategies and more. Canaccord says that on a post-earn-out basis, Trulieve paid roughly 5x their 2021 EBITDA assumptions for PurePenn and Solevo. On Thursday, Zuanic said he sees the deals as a positive for Trulieve, but noted that “we do not like the timing” of the offering. Trulieve Cannabis (CSE: TRUL) reported their second-quarter financial results this week, boasting a record U$120.8 million in revenue, up 26% quarter to quarter, and above Refinitiv’s estimate of U$106.1 million.
Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Always do additional research and consult a professional before purchasing a security. Not a recommendation to buy or sell securities. In addition to naming Trulieve and Green Thumb as his top U.S. cannabis stock picks, the Cantor analyst also reiterated his “Overweight” rating on shares of TRUL and GTII. Need some freelance work done? We’re experienced in many forms of writing, including press releases. With the price target upgrade, Dley has upgraded his fiscal year 2021 estimates for Trulieve. The analyst says that Trulieve has doubled its weekly sales of concentrate and dry flower in the last seven months thanks to same-store sales increasing 30% quarter over quarter, and customers visiting a Trulieve store 2.7x per month while having an average basket of $125.
Featured Story: What Is An Exchange-Traded Fund (ETF)?